RS Biotherapeutics Inc.
09/23/2026 | Press release | Distributed by Public on 09/23/2026 04:02
Annual Report by Private Issuer (Form C-AR)
| FORM C |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
OMB APPROVAL |
|
|
OMB Number: ####-#### Estimated average burden hours per response: ##.# |
Form C: Filer Information
| Filer CIK: |
0001932193
|
| Filer CCC: |
XXXXXXXX
|
| File Number: |
020-34040
|
| Period: |
12-31-2025
|
| Is this a LIVE or TEST Filing? | LIVE TEST |
| Is this an electronic copy of an official filing submitted in paper format in connection with a hardship exemption? | |
| Would you like a Return Copy? |
Submission Contact Information
| Name: |
|
| Phone Number: |
|
| Contact E-Mail Address: |
|
| Notify via Filing Website only? |
Form C: Issuer Information
Issuer Information
| Name of Issuer: |
RS BioTherapeutics, Inc.
|
Legal Status of Issuer:
| Form: |
Corporation
|
| Jurisdiction of Incorporation/Organization: |
DELAWARE
|
| Date of Incorporation/Organization: |
02-08-2021
|
Physical Address of Issuer:
| Address 1: |
157 Baltimore St. Suite 140
|
| City: |
Cumberland
|
| State/Country: |
MARYLAND
|
| Mailing Zip/Postal Code: |
21502
|
| Website of Issuer: |
http://rsbiotherapeutics.com
|
Form C: Offering Information
Offering Information
Form C: Annual Report Disclosure Requirements
Annual Report Disclosure Requirements
| Current Number of Employees: |
2
|
| Total Assets Most Recent Fiscal Year-end: |
13807.63
|
| Total Assets Prior Fiscal Year-end: |
40617.00
|
| Cash and Cash Equivalents Most Recent Fiscal Year-end: |
9302.63
|
| Cash and Cash Equivalents Prior Fiscal Year-end: |
14158.00
|
| Accounts Receivable Most Recent Fiscal Year-end: |
0.00
|
| Accounts Receivable Prior Fiscal Year-end: |
0.00
|
| Short-term Debt Most Recent Fiscal Year-end: |
1249122.90
|
| Short-term Debt Prior Fiscal Year-end: |
589895.00
|
| Long-term Debt Most Recent Fiscal Year-end: |
188555.05
|
| Long-term Debt Prior Fiscal Year-end: |
188555.00
|
| Revenue/Sales Most Recent Fiscal Year-end: |
1778.76
|
| Revenue/Sales Prior Fiscal Year-end: |
0.00
|
| Cost of Goods Sold Most Recent Fiscal Year-end: |
0.00
|
| Cost of Goods Sold Prior Fiscal Year-end: |
0.00
|
| Taxes Paid Most Recent Fiscal Year-end: |
2835.68
|
| Taxes Paid Prior Fiscal Year-end: |
0.00
|
| Net Income Most Recent Fiscal Year-end: |
-204030.79
|
| Net Income Prior Fiscal Year-end: |
-2204226.00
|
Form C: Signature
Signature
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.| Issuer: |
RS BioTherapeutics, Inc.
|
| Signature: |
Justin Molignoni
|
| Title: |
Chairman of the Board, Chief Strategy Officer
|
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.
| Signature: |
Justin Molignoni
|
| Title: |
Chairman of the Board, Chief Strategy Officer
|
| Date: |
09-22-2026
|
RS Biotherapeutics Inc. published this content on September 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 23, 2026 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]